Clinical Trial

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Study acronym: SCD Depo
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2028-07 -> 2028-07-31 2026-05-29
minor Completion pushed: 2028-07 -> 2028-07-31 2026-05-29
notable Primary completion pushed: 2027-10 -> 2028-07 2026-05-14
minor Completion pushed: 2027-10 -> 2028-07 2026-05-14
Trial Details
NCT Number NCT06665997
Lead Sponsor University of Pennsylvania
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Emory University, Children's Hospital of Philadelphia
Conditions Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Enrollment 65 participants
Start Date 2025-06-26
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-28